Eupraxia Pharmaceuticals Inc. EPRX
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 13, 2026
Eupraxia Pharmaceuticals Inc. (EPRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $38.6 million. As of Dec 31, 2025 it held $80.6 million in cash and investments and $154,362 in total debt.
Revenue
$0
Net income
$-38.58M
-51.3% vs prior year
Operating cash flow
$-28.55M
+4.8% vs prior year
Free cash flow
—
EPS
$-1.03
-35.5% vs prior year
Dividend per share
None
Shares outstanding
51.94M
+45.7% vs prior year
Net cash
$80.41M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1581178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net income | -$38.6M | -$25.5M | -$28.2M |
| Diluted EPS | -$1.03 | -$0.76 | -$1.17 |
| Operating cash flow | -$28.6M | -$30.0M | -$20.7M |
| Total assets | $86.2M | $34.9M | $20.3M |
| Total liabilities | $5.7M | $3.1M | $19.4M |
| Stockholders' equity | $82.0M | $33.4M | $2.2M |
| Cash and investments | $80.6M | $33.1M | $19.3M |
| Total debt | $154,362 | $71,859 | $53,316 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 9, 2026 | Oct 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
All 126 Eupraxia Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.